In 1994, Amgen Inc. acquired Synergen Inc.'s product pipeline and $120 million in cash for $240 million. Nearly three years later, nothing in that pipeline has progressed past Phase I/II testing, and now AMGN is looking for a partner to help share the costs of developing all but one product candidate.

The products about to be shopped around comprise the majority of AMGN's inflammation pipeline, located in the company's Boulder, Colo., facilities where Synergen was based.